Insider transactions

EDGAR

Jade Biosciences, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-18.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–14 of 14

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-06-25 Filed 2026-06-26Eisner Mark Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (47,675) — exercise price 21.81
Acquired (A)47,6750—47,675Direct (D) No
F1
  • F1 1/36th of the total number of shares of common stock subject to the option vest monthly following the date of grant, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Open filing 0001193125-26-286434 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Klein Lawrence Otto Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (34,843) — exercise price 15.22
Acquired (A)34,8430—34,843Direct (D) No
F1
  • F1 This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Open filing 0001193125-26-267735 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Fairmount Funds Management LLC Director · 10% ownerFairmount Healthcare Fund II L.P. Director · 10% ownerFairmount Healthcare Co-Invest IV L.P. Director · 10% ownerKiselak Tomas Director · 10% ownerHarwin Peter Evan Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (34,843) — exercise price 15.22
Acquired (A)34,8430—34,843Direct (D) No
F1, F2
  • F1 This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to Tomas Kiselak's continued service to the Issuer.
  • F2 Fairmount Funds Management LLC (Fairmount) is the investment manager for Fairmount Healthcare Fund II LP (Fund II) and Fairmount Healthcare Co-Invest IV L.P. (Co-Invest). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a Fairmount Fund). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Open filing 0001193125-26-267706 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11CAIN CHRISTOPHER W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (34,843) — exercise price 15.22
Acquired (A)34,8430—34,843Direct (D) No
F1, F2
  • F1 This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
  • F2 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (Fairmount), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a Fairmount Fund). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.
Open filing 0001193125-26-267764 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11DOBMEIER ERIC Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (34,843) — exercise price 15.22
Acquired (A)34,8430—34,843Direct (D) No
F1
  • F1 This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Open filing 0001193125-26-267739 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Lavelle Erin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (34,843) — exercise price 15.22
Acquired (A)34,8430—34,843Direct (D) No
F1
  • F1 This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Open filing 0001193125-26-267708 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13Frohlich Tom Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)78,7500—86,331Direct (D) No
F1, F2
  • F1 Represents restricted stock units (RSUs). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  • F2 Includes 1,581 shares acquired under the Issuer's employee stock purchase plan in December 2025.
Open filing 0001193125-26-052054 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13Frohlich Tom Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (472,500) — exercise price 14.81
Acquired (A)472,5000—472,500Direct (D) No
F3
  • F3 This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Open filing 0001193125-26-052054 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13King Andrew James Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)41,2500—386,113Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-052053 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13King Andrew James Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (247,500) — exercise price 14.81
Acquired (A)247,5000—247,500Direct (D) No
F2
  • F2 This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Open filing 0001193125-26-052053 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13Dahms Bradford D. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)37,8130—37,813Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-052056 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13Dahms Bradford D. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (226,875) — exercise price 14.81
Acquired (A)226,8750—226,875Direct (D) No
F2
  • F2 This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Open filing 0001193125-26-052056 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13Balta Elizabeth Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)28,1250—28,125Direct (D) No
F1
  • F1 Represents restricted stock units (RSUs). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Open filing 0001193125-26-052055 Read from the filing’s XML Dispute this row
2026-02-12 Filed 2026-02-13Balta Elizabeth Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (168,750) — exercise price 14.81
Acquired (A)168,7500—168,750Direct (D) No
F2
  • F2 This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Open filing 0001193125-26-052055 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.

Showing 1–50 of 167

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
FMR LLC Partly reported under another manager9,810,088 SH137,831,737 dollarsHigher by 683,211 Prior quarter: 9,126,877Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Janus Henderson Group Ltd. Partly reported under another manager6,991,676 SH98,113,949 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
Paradigm Biocapital Advisors LP 6,053,268 SH85,048,415 dollarsHigher by 3,195,863 Prior quarter: 2,857,405Open filing 0001855655-26-000020 Filed 2026-11-16 Dispute this row
Fairmount Funds Management LLC 4,553,494 SH63,976,591 dollarsUnchanged Prior quarter: 4,553,494Open filing 0001104659-26-128188 Filed 2026-11-16 Dispute this row
Bellevue Group AG Partly reported under another manager4,293,937 SH60,329,815 dollarsHigher by 1,235,941 Prior quarter: 3,057,996Open filing 0001104659-26-128575 Filed 2026-11-16 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager3,807,236 SH57,260,829 dollarsHigher by 1,015,156 Prior quarter: 2,792,080Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
BlackRock, Inc. Partly reported under another manager3,366,725 SH47,302,485 dollarsHigher by 565,274 Prior quarter: 2,801,451Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Venrock Adviser, LLC 3,220,364 SH45,246,114 dollarsUnchanged Prior quarter: 3,220,364Open filing 0001615982-26-000019 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager2,602,939 SH36,571,293 dollarsHigher by 267,654 Prior quarter: 2,335,285Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,345,833 SH32,958,954 dollarsHigher by 101,060 Prior quarter: 2,244,773Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Avidity Partners Management LP 2,000,000 SH28,100,000 dollarsHigher by 299,292 Prior quarter: 1,700,708Open filing 0001791827-26-000008 Filed 2026-11-16 Dispute this row
Polar Capital Holdings Plc Partly reported under another manager1,843,717 SH25,904,224 dollarsLower by 3,265 Prior quarter: 1,846,982Open filing 0001172661-26-005169 Filed 2026-11-16 Dispute this row
RA CAPITAL MANAGEMENT, L.P. 1,835,542 SH25,789,365 dollarsLower by 1,835,541 Prior quarter: 3,671,083Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
Remedium Capital Partners, LLC Partly reported under another manager1,807,814 SH25,399,787 dollarsHigher by 230,064 Prior quarter: 1,577,750Open filing 0002104501-26-000021 Filed 2026-11-13 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager1,469,144 SH20,832,463 dollarsLower by 5,935 Prior quarter: 1,475,079Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager1,397,736 SH19,639 dollarsHigher by 1,371,190 Prior quarter: 26,546Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
BAKER BROS. ADVISORS LP 1,230,426 SH17,287,485 dollarsUnchanged Prior quarter: 1,230,426Open filing 0001104659-26-128308 Filed 2026-11-16 Dispute this row
Pictet Asset Management Holding SA 1,205,972 SH16,943,907 dollarsHigher by 472,204 Prior quarter: 733,768Open filing 0001993888-26-000007 Filed 2026-11-03 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,201,913 SH16,892,198 dollarsHigher by 216,735 Prior quarter: 985,178Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Soleus Capital Management, L.P. 1,170,928 SH16,451,538 dollarsLower by 379,762 Prior quarter: 1,550,690Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row
Versant Venture Management, LLC 991,783 SH13,934,551 dollarsUnchanged Prior quarter: 991,783Open filing 0001193125-26-460919 Filed 2026-11-13 Dispute this row
ACORN CAPITAL ADVISORS, LLC 986,760 SH13,863,978 dollarsUnchanged Prior quarter: 986,760Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 950,000 SH13,347,500 dollarsLower by 960,812 Prior quarter: 1,910,812Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager929,291 SH13,056,539 dollarsLower by 116 Prior quarter: 929,407Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager896,834 SH12,600,518 dollarsHigher by 161,610 Prior quarter: 735,224Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Foresite Capital Management VI LLC 886,667 SH12,457,671 dollarsUnchanged Prior quarter: 886,667Open filing 0001104659-26-128383 Filed 2026-11-16 Dispute this row
Affinity Asset Advisors, LLC 760,350 SH10,682,918 dollarsLower by 80,000 Prior quarter: 840,350Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row
SAMSARA BIOCAPITAL, LLC 736,237 SH10,344,130 dollarsUnchanged Prior quarter: 736,237Open filing 0001744967-26-000014 Filed 2026-11-16 Dispute this row
Blackstone Inc. Partly reported under another manager676,596 SH9,506,174 dollarsHigher by 241,276 Prior quarter: 435,320Open filing 0001193125-26-463513 Filed 2026-11-16 Dispute this row
LORD, ABBETT CO. LLC 666,923 SH9,370 dollarsHigher by 440,317 Prior quarter: 226,606Open filing 0000930413-26-003314 Filed 2026-11-13 Dispute this row
Aberdeen Group plc Partly reported under another manager550,887 SH7,739,962 dollarsLower by 70,221 Prior quarter: 621,108Open filing 0001716774-26-000032 Filed 2026-11-10 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager528,368 SH7,423,570 dollarsHigher by 328,939 Prior quarter: 199,429Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 521,682 SH7,329,632 dollarsHigher by 60,154 Prior quarter: 461,528Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
STEMPOINT CAPITAL LP 471,718 SH6,627,638 dollarsNot in the prior quarter’s filings read Open filing 0001420506-26-002774 Filed 2026-11-16 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager458,886 SH6,447,348 dollarsLower by 126,875 Prior quarter: 585,761Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 444,165 SH6,240,518 dollarsHigher by 344,188 Prior quarter: 99,977Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC 427,349 SH6,004,253 dollarsUnchanged Prior quarter: 427,349Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 420,542 SH5,908,615 dollarsHigher by 105,994 Prior quarter: 314,548Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 382,478 SH5,373,816 dollarsHigher by 215,274 Prior quarter: 167,204Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager381,317 SH5,357,505 dollarsHigher by 86,236 Prior quarter: 295,081Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 364,632 SH5,123,080 dollarsHigher by 59,765 Prior quarter: 304,867Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 342,285 SH4,809,104 dollarsHigher by 125,128 Prior quarter: 217,157Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
Jump Financial, LLC Partly reported under another manager302,812 SH4,254,508 dollarsHigher by 130,065 Prior quarter: 172,747Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
Cormorant Asset Management, LP Partly reported under another manager300,000 SH4,215,000 dollarsNot in the prior quarter’s filings read Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row
SCHRODER INVESTMENT MANAGEMENT GROUP Partly reported under another manager262,316 SH3,719,641 dollarsHigher by 121,430 Prior quarter: 140,886Open filing 0001140361-26-044129 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager221,367 SH3,110,206 dollarsHigher by 93,790 Prior quarter: 127,577Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
XTX Topco Ltd Partly reported under another manager218,952 SH3,076,276 dollarsHigher by 159,859 Prior quarter: 59,093Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
Logos Global Management LP 200,000 SH2,810,000 dollarsLower by 925,000 Prior quarter: 1,125,000Open filing 0001172661-26-005128 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager189,998 SH2,669,472 dollarsLower by 296,957 Prior quarter: 486,955Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Walleye Capital LLC 180,462 SH2,535,491 dollarsLower by 184,810 Prior quarter: 365,272Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Jupiter Topco LLC 6,273,262 SH
  • Balyasny Asset Management L.P. 878,726 SH
  • Sixth Street Partners Management Company, L.P. 99,977 SH
  • Atle Fund Management AB 88,556 SH
  • Longaeva Partners L.P. 78,501 SH
  • Corient Private Wealth LP 61,530 SH
  • Maven Securities LTD 50,000 SH
  • VOLORIDGE INVESTMENT MANAGEMENT, LLC 48,374 SH
  • Voleon Capital Management LP 27,777 SH
  • Engineers Gate Manager LP 22,619 SH
  • Aquatic Capital Management LLC 22,431 SH
  • Ghisallo Capital Management LLC 20,000 SH
  • AQR CAPITAL MANAGEMENT LLC 13,311 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 11,522 SH
  • Values First Advisors, Inc. 11,191 SH
  • DELTEC ASSET MANAGEMENT LLC 9,436 SH
  • MERCER GLOBAL ADVISORS INC /ADV 4,930 SH
  • STRS OHIO 3,300 SH
  • Pacer Advisors, Inc. 712 SH
  • Optiver Holding B.V. 104 SH
  • Integrated Wealth Concepts LLC 53 SH
  • Quarry LP 39 SH
  • NATIONAL BANK OF CANADA /FI/ 23 SH
  • Ares Financial Consulting, LLC 20 SH
  • Stone House Investment Management, LLC 8 SH
  • Avion Wealth 7 SH
  • Clearstead Advisors, LLC 3 SH
  • Wealth Enhancement Trust Services, Inc. 1 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share9.56,053,268.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128317 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share9.56,053,268.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128317 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.0001 par value per share9.56,053,268.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128317 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share8.45,335,522.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128317 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share2.91,835,542.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000283 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share2.91,835,542.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000283 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share2.91,835,542.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000283 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share2.91,835,542.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000283 Dispute this row
Bellevue Group AG Common Stock6.84,293,937.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-128591 Dispute this row
Bellevue Asset Management AG Common Stock6.84,293,937.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-128591 Dispute this row
Venrock Healthcare Capital Partners III, L.P. Common Stock, $0.0001 par value per share5.93,858,984.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001738048-26-000094 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, $0.0001 par value per share5.93,858,984.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001738048-26-000094 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, $0.0001 par value per share5.93,858,984.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001738048-26-000094 Dispute this row
VHCP Management III, LLC Common Stock, $0.0001 par value per share5.93,858,984.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001738048-26-000094 Dispute this row
VHCP Management EG, LLC Common Stock, $0.0001 par value per share5.93,858,984.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001738048-26-000094 Dispute this row
Nimish Shah Common Stock, $0.0001 par value per share5.93,858,984.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001738048-26-000094 Dispute this row
Bong Y. Koh Common Stock, $0.0001 par value per share5.93,858,984.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0001738048-26-000094 Dispute this row
Franklin Templeton, Inc. Common Stock, par value $0.0001 per share6.03,807,236.0009/30/2026 Filed 2026-10-28SCHEDULE 13GOpen filing 0000038777-26-000277 Dispute this row
Charles B. Johnson Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-10-28SCHEDULE 13GOpen filing 0000038777-26-000277 Dispute this row
Rupert H. Johnson, Jr. Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-10-28SCHEDULE 13GOpen filing 0000038777-26-000277 Dispute this row
BlackRock, Inc. Common Stock5.23,323,30109/30/2026 Filed 2026-10-27SCHEDULE 13GOpen filing 0002012383-26-003871 Dispute this row
Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share5.13,106,793.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001104659-26-084623 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share5.13,106,793.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001104659-26-084623 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.0001 par value per share5.13,106,793.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001104659-26-084623 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share4.52,738,259.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001104659-26-084623 Dispute this row
Bellevue Group AG Common Stock5.03,057,996.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-096751 Dispute this row
Bellevue Asset Management AG Common Stock5.03,057,996.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-096751 Dispute this row
Venrock Healthcare Capital Partners III, L.P. Common Stock, $0.0001 par value8.35,145,330.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000932 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, $0.0001 par value8.35,145,330.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000932 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, $0.0001 par value8.35,145,330.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000932 Dispute this row
VHCP Management III, LLC Common Stock, $0.0001 par value8.35,145,330.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000932 Dispute this row
VHCP Management EG, LLC Common Stock, $0.0001 par value8.35,145,330.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000932 Dispute this row
Nimish Shah Common Stock, $0.0001 par value8.35,145,330.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000932 Dispute this row
Bong Y. Koh Common Stock, $0.0001 par value8.35,145,330.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001231919-26-000932 Dispute this row
JANUS HENDERSON GROUP Ltd. Common Stock10.66,273,26206/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 2Open filing 0001274173-26-000169 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.0001 par value per share19.9914,069,494.0006/05/2026 Filed 2026-06-09SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-071942 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.0001 par value per share16.2211,413,677.0006/05/2026 Filed 2026-06-09SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-071942 Dispute this row
Fairmount Healthcare Co-Invest IV L.P. Common Stock, $0.0001 par value per share4.362,655,817.0006/05/2026 Filed 2026-06-09SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-071942 Dispute this row
Peter Evan Harwin Common Stock, $0.0001 par value per share19.9914,069,494.0006/05/2026 Filed 2026-06-09SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-071942 Dispute this row
Tomas Kiselak Common Stock, $0.0001 par value per share19.9914,063,511.0006/05/2026 Filed 2026-06-09SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-071942 Dispute this row
JANUS HENDERSON GROUP PLC Common Stock6.33,105,66903/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001274173-26-000147 Dispute this row
BlackRock, Inc. Common Stock4.72,295,82503/31/2026 Filed 2026-04-27SCHEDULE 13G/AAmendment 2Open filing 0002012383-26-001731 Dispute this row
Venrock Healthcare Capital Partners III, L.P. Common Stock, $0.0001 par value9.95,115,862.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000022 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, $0.0001 par value9.95,115,862.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000022 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, $0.0001 par value9.95,115,862.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000022 Dispute this row
VHCP Management III, LLC Common Stock, $0.0001 par value9.95,115,862.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000022 Dispute this row
VHCP Management EG, LLC Common Stock, $0.0001 par value9.95,115,862.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000022 Dispute this row
Nimish Shah Common Stock, $0.0001 par value9.95,115,862.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000022 Dispute this row
Bong Y. Koh Common Stock, $0.0001 par value9.95,115,862.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001738048-26-000022 Dispute this row
JANUS HENDERSON GROUP PLC Common Stock6.23,063,45712/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0001274173-26-000080 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,256,735 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
2022158,941
2023199,811
2024209,823
2025235,520
2026260,174

Filings made before the SEC required XML are listed, not extracted.

Back to Jade Biosciences, Inc.